Phase 1: Healthy Volunteers: The drug is first given to a small group of healthy people at very low doses. The goal here is purely to check for safety and side effects in a functioning human body, not to treat a disease.
Phase 2 & 3: Patient Trials: If found safe, the drug is administered to people suffering from the target illness. These larger trials determine the drug's efficacy and help refine the optimum dosage for the general population.
Double-Blind Studies: To eliminate bias, trials often use a 'double-blind' design where neither the patient nor the doctor knows who is receiving the real drug and who is receiving a placebo. This ensures that the reported results are due to the drug's chemistry rather than psychological expectations.
| Feature | Preclinical Testing | Clinical Trials |
|---|---|---|
| Subjects | Cells, tissues, and animals | Human volunteers and patients |
| Primary Goal | Toxicity and basic efficacy | Safety, optimum dose, and human efficacy |
| Environment | Controlled laboratory setting | Medical facilities and real-world scenarios |
| Regulation | Internal and ethical review | Strict government and peer-review oversight |
Sequence Awareness: Always remember the chronological order: Cells Animals Healthy Humans Patients. Exams often ask students to identify where a specific test fits in this timeline.
Terminology Precision: Distinguish clearly between 'toxicity' (is it harmful?) and 'efficacy' (does it work?). Using these terms correctly is vital for gaining full marks in descriptive questions.
The Role of the Placebo: Be prepared to explain that a placebo is an inactive substance used as a control. It allows researchers to prove that the drug's effects are statistically significant compared to doing nothing.
Peer Review Importance: Understand that results are not accepted until they have been scrutinized by independent scientists. This process prevents false claims and ensures data integrity.
